Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Electromed manufactures and markets the SmartVest Airway Clearance System, a high-frequency chest wall oscillation (HFCWO) device used primarily for treating bronchiectasis, cystic fibrosis, and neuromuscular disorders. The company operates in a specialized medical device niche with direct-to-patient sales and reimbursement through Medicare, Medicaid, and private insurers. With zero debt, 78% gross margins, and 20% ROE, Electromed demonstrates strong unit economics in a recurring revenue model driven by device placements and ongoing therapy supplies.
Electromed generates revenue through a reimbursement-driven model where patients receive prescriptions for HFCWO therapy, and the company bills Medicare/Medicaid or private insurers directly. The SmartVest system typically reimburses at $7,000-$15,000 per unit depending on payer mix. Competitive advantages include: (1) proprietary triangle waveform technology claimed to provide superior mucus clearance versus competitors like RespirTech and Hillrom, (2) direct sales force with clinical specialists who educate pulmonologists and build referral networks, (3) established reimbursement codes and payer relationships reducing friction in the sales cycle. The 78% gross margin reflects low manufacturing costs relative to reimbursement rates, while operating leverage comes from spreading fixed sales/marketing costs across growing unit volumes.
Quarterly device placement volumes and average selling prices (ASPs) - unit growth drives topline expansion
Medicare reimbursement rate changes or coverage policy updates affecting HFCWO therapy codes
Sales force productivity metrics - new hires, ramp time, and placements per rep trends
Competitive wins/losses against Hillrom (Baxter) and RespirTech in hospital/pulmonology networks
Clinical trial results or publications supporting HFCWO efficacy in new indications (COPD, post-COVID bronchiectasis)
Medicare reimbursement cuts or policy changes restricting HFCWO coverage - CMS periodic reviews could reduce payment rates or tighten medical necessity criteria, directly impacting revenue per placement
Technological disruption from alternative airway clearance methods - newer portable devices, pharmaceutical mucolytics, or gene therapies for cystic fibrosis could reduce HFCWO utilization over 5-10 year horizon
Regulatory pathway changes requiring more extensive clinical evidence for device approvals or reimbursement, increasing R&D costs and time-to-market for product iterations
Market share erosion to Hillrom/Baxter's Vest system leveraging broader hospital relationships and integrated respiratory care portfolios - larger competitors can bundle HFCWO with ventilators and monitoring systems
Price competition from smaller entrants or refurbished device markets compressing ASPs and gross margins, particularly in cost-sensitive Medicaid and international markets
Minimal financial risk given zero debt and 4.86x current ratio - balance sheet is overcapitalized with excess cash potentially underutilized
Inventory obsolescence risk if product refresh cycles accelerate or reimbursement policies shift toward rental models over outright purchases, though current 78% gross margins provide cushion
low - Medical device demand for chronic respiratory conditions is non-discretionary and driven by clinical need rather than economic cycles. However, commercial insurance enrollment (tied to employment) affects payer mix, with higher unemployment potentially shifting patients to Medicaid with lower reimbursement rates. The 17% revenue growth during recent periods suggests resilience, but severe recessions could pressure hospital capital budgets for initial device stocking.
Rising interest rates have minimal direct impact on operations given zero debt and strong cash generation ($0.0B operating cash flow appears to be a data reporting issue given 5.2% FCF yield implies ~$10M annual FCF on $200M market cap). However, higher rates compress valuation multiples for growth stocks, particularly affecting the 3.1x P/S ratio. The company's cash-rich balance sheet (4.86 current ratio) benefits from higher yields on invested cash, providing modest tailwinds to net interest income.
minimal - The business model relies on government and insurance reimbursement rather than consumer credit. Patients typically have no out-of-pocket costs after prior authorization. Credit risk is limited to accounts receivable from payers, with Medicare/Medicaid representing low default risk. Private insurer payment delays could affect working capital but pose minimal structural risk.
growth - The 17% revenue growth, 46% net income growth, and 50% EPS growth attract growth-oriented investors seeking small-cap healthcare exposure. The zero-debt balance sheet and 20% ROE appeal to quality-focused growth investors. However, the $200M market cap limits institutional ownership, making this primarily a retail and small-cap fund holding. The -14% one-year return followed by 34% six-month recovery suggests momentum traders also participate during growth acceleration phases.
high - Small-cap medical device stocks with <$500M market cap typically exhibit 30-40% annualized volatility due to limited float, low analyst coverage, and binary outcomes from reimbursement decisions or competitive dynamics. The 34% six-month surge followed by -14% annual return demonstrates characteristic volatility. Quarterly earnings beats/misses can drive 15-25% single-day moves given thin trading volumes.
